Novo Nordisk's latest trial results for its next-generation obesity drug CagriSema disappointed investors by failing to show superior outcomes to existing drugs. CagriSema, which includes a ...

Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy. Here's what we know so far about this promising new option for those ...

Novo Nordisk A/S' CagriSema disappointed investors again, but today's update should not have surprised anyone. The flexible dosing protocol in the REDEFINE trials likely led to suboptimal efficacy ...

REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo.

CagriSema-treated patients achieved superior weight loss compared with those who received placebo. Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide 2.4mg and ...

At 68 weeks, 89.7% of adults with obesity and type 2 diabetes lost 5% or more body weight with CagriSema. Detailed results from the REDEFINE 1 and REDEFINE 2 trials will be presented later in 2025.

New trial data showed CagriSema led to 'superior' weight loss, but at a rate less than expectations Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

Besides Ozempic and Wegovy, the company has made progress recently on other obesity drugs in its pipeline, including amycretin and CagriSema. It has announced plans to invest billions to expand ...

Three months after missing that target in its first phase 3 CagriSema trial, the Danish drugmaker has fallen even further short of that bar in the second study. With Eli Lilly setting the pace on ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...